Category: CBDs
-
![Canntab Therapeutics (PILL.C): The Canadian weed sector is struggling, but new consumer products have room to scale]()
Canntab Therapeutics (PILL.C): The Canadian weed sector is struggling, but new consumer products have room to scale
If we’re honest about it – if we’re REALLY honest about it – Canada has fumbled its advantage in the cannabis sector. First to market, first to raise hundreds of millions in financing, first to legalize, first to recreationalize (not a word but I’m on a roll), and it’s all really been for naught. In…
-
![Pure Extracts (PULL.C) begins mushroom build-out]()
Pure Extracts (PULL.C) begins mushroom build-out
Pure Extracts is targeting the commercial cannabis and psychedelics sector, backed by deep extraction and production expertise.
-
Heritage Cannabis (CANN.C) up hard on Alberta sales news
No cannabis companies splits investors squarely down the middle like Heritage Cannabis (CANN.C). Despite ongoing good news and deals with larger players, a sizable section of the legacy cannabis investing community has just never been able to get on board with the Canadian weedco – until this week. Our Joseph Morton blew the trumpet on…
-
![Core One Labs (COOL.C) unhalted today, and it will be a horror show: But that’s okay]()
Core One Labs (COOL.C) unhalted today, and it will be a horror show: But that’s okay
Halted since July of this year, right in the midst of a six week rise, the pubco formerly known as Lifestyle Delivery Systems, now Core One Labs (COOL.C), unhalted today and, as expected, took an immediate stock price dive. Having shut the door to trading in July at $0.73 as the exchange enforced a change…
-
Canntab Therapeutics’ (PILL.C) bursts out of the starting blocks with $1.3 million sale
PILL is developing solid oral dose formulations of cannabis with a product line of cannabinoid (THC & CBD) and terpenoid blends in multiple doses and timed-release combinations
-
Cannabis extractor Pure Extracts (PULL.C) stakes claim in the rocketing mushroom space
Barely a few weeks after telling the Equity.Guru audience that the timeline on mushrooms would see Pure Extracts (PULL.C) focusing on its core cannabis market, evolving market dynamics and a renewed focus on the potential of psychedelics have seen the company hit the gas on its long term shroom plans. With interest in functional and…
-
Pure Extracts (PULL.C) goes public with profit-focused cannabis (and mushroom) extraction business model
Yeah, I know, I know. Canadian cannabis companies are ass right now, and have been for a few years. Trust me, I’m about as out of the LP business now as I’ve ever been, but you’d also be an idiot to tar every cannabis company with the same brush, because not every deal involves growing…
-
![Heritage Cannabis (CANN.C) granted oil sales licence – CannaCure’s Fort Erie facility in focus]()
Heritage Cannabis (CANN.C) granted oil sales licence – CannaCure’s Fort Erie facility in focus
CannaCure’s goal is “to transform the global marijuana landscape through innovative growth strategies and strategic partnerships with manufacturers of cannabis products.”
-
Watch me: I can sell you on CLS Holdings (CLSH.C), with its one dispensary, being a better buy than Trulieve (TRUL.C), with 52
Let’s take a step back. Take a breath. Maybe meditate or toss back a tequila shot. Okay, we good for a chat? It’s been a rough few years for the cannabis crowd, and a rough last year for everyone else. With Aurora Cannabis (ACB.T) losing the gross national product of Panama, Chuck Rifici bailing from…
-
Heritage Cannabis (CANN.C) is so close profitability, it’s breaking social distancing rules
Sharples believes that Purefarma, Pura Vida, new contract manufacturing agreements, expansion of Canadian territories, the edibles product launch and the acquisition of Opticann expanding CANN’s U.S. presence will accelerate revenue going forward.
